A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy

Nephrology Dialysis Transplantation

Volumn 19, Issue 8, 2004, Pages 2113-2120

  Stoves, John ^a,d   Newstead, Charles G ^a   Baczkowski, Andrew J ^b   Owens, Geoffrey ^c   Paraoan, Marius ^c   Hammad, Abdul Q ^c  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^d ST LUKE S HOSPITAL   (United Kingdom)

Author keywords

Chronic allograft nephropathy; Cyclosporin; Glomerular filtration rate; Mycophenolate mofetil; Randomized controlled trial; Tacrolimus

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACNE; ACUTE DISEASE; ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIALYSIS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG TOLERANCE; EAR INFECTION; GASTROINTESTINAL SYMPTOM; GOUT; HAIR LOSS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DISEASE; PERIANAL ABSCESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT INFECTION;

CHRONIC DISEASE; CYCLOSPORINE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 4344695166     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh188     Document Type: Article

References (21)

1. UK Transplant. Renal Transplant Audit 1990-1998. UK Transplant, Bristol, 2001
2. Fritsche L, Sperschneider H, Budde K. Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients. Transplant Proc 1998; 30: 1190-1191
3. Weir MR, Anderson L, Finf JC et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64: 1706-1710
4. Islam MS, Francos GC, Dunn SR, Burke JF. Mycophenolate mofetil and reduction in cyclosporine dosage for chronic renal allograft dysfunction. Transplant Proc 1998; 30: 2230-2231
5. Glicklich D, Gupta B, Schurter-Frey G et al. Chronic renal allograft rejection: no response to MMF. Transplantation 1998; 66: 398-399
6. Kliem V, Boeck A, Eisenberger U. Treatment of chronic renal allograft failure by addition of mycophenolate mofetil: single-centre experience in 40 patients. Transplant Proc 1999; 31: 1312-1313
7. Campistol JM, Mazuecos A, Segura J et al. Mycophenolate mofetil slows the decline of renal function in patients with biopsy-proven chronic rejection: a collaborative pilot study. Transplant Proc 1999; 31: 2267-2269
8. Gonzalez Molina M, Seron D, Garcia del Moral R et al. Treatment of chronic allograft nephropathy with mycophenolate mofetil after kidney transplantation. A Spanish multicentre study. Nephrol Dial Transplant 2001; 16: A207
9. Morris-Stiff G, Baboolal K, Dunstan F, Jurewicz WA. Conversion from cyclosporin (Neoral) to tacrolimus (Prograf) in renal allograft recipients with chronic allograft nephropathy: results of an observational study. Transplant Int 1998; 11: 598-599
10. Manu MA, Tanabe K, Ishikawa N et al. Tacrolimus rescue for resistant rejection, chronic rejection and IgA nephropathy of renal allografts under primary cyclosporine A immunosuppression. Transplant Proc 1999; 31: 2853-2855
11. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1194-1197
12. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723
13. Dubois D, Dubois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med 1916; 17: 863-871
14. Dudley CRK, the Mycophenolate Mofetil Creeping Creatinine Study Group. Mycophenolate mofetil substitution for cyclosporine withdrawal is an effective and safe treatment of chronic allograft dysfunction; results of a multi-center randomized controlled study. Am J Transplant 2002; 2 [Suppl 3]: 148A
15. Velosa JA, Grande JP, Larson TS et al. Rate of decline in GFR in patients with chronic allograft nephropathy: effect of calcineurin inhibitors. Am J Transplant 2001; 1 [Suppl 1]: 618A
16. Curtis JJ, Luke RG, Dubovsky E, Diethelm AG, Whelchel JD, Jones P. Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 1986; 2: 477-479
17. Shihab FS, Andoh TF, Tanner AM et al. Role of TGF-beta 1 in experimental chronic cyclosporin nephropathy. Kidney Int 1996; 49: 1141-1151
18. Azuma H, Binder J, Heemann U, Schmid C, Tullius SG, Tilney NL. Effects of R561443 on function and morphological changes in chronically rejecting rat kidney allografts. Transplantation 1995; 59: 460-466
19. Zeier M, Deppisch R, Waldherr R, Adams J, Schwenger V, Ritz E. Fibroblast growth is inhibited by mycophenolic acid. Nephrol Dial Transplant 2001; 16: A207
20. Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405-2409
21. Stoves J, Newstead CG, Allgar VA, Will EJ, Davison AM. Elective withdrawal of cyclosporin following renal transplantation: a single centre experience. Nephrology 2002; 7: 29-32